Structural Insights into HCAR3 Agonist Selectivity via Cryo-EM

Study Background and Research Question

The hydroxycarboxylic acid receptors HCAR2 and HCAR3 (also known as HM74A/GPR109A and GPR109B, respectively) are G-protein coupled receptors (GPCRs) central to the regulation of lipid metabolism and are considered key targets in metabolic disorder research. While HCAR2 activation is associated with adverse effects such as cutaneous flushing, HCAR3's structural features and ligand selectivity have remained less well understood. This knowledge gap impedes the development of hypolipidemic agents for lipid metabolism research that avoid HCAR2-mediated side effects. The central question addressed by Ye et al. (2025) is: What are the structural determinants underlying ligand recognition and selectivity in HCAR3, and how do these differ from HCAR2?

Key Innovation from the Reference Study

The primary innovation of Ye et al. lies in the determination of high-resolution cryo-EM structures of HCAR3 in complex with multiple selective agonists—including Acifran ((R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid)—and the parallel structure of HCAR2 with Acifran. This work provides the first direct visualization of the molecular interactions that govern ligand binding and selectivity in HCAR3, revealing critical features that distinguish it from HCAR2. Notably, the study clarifies why certain agonists, such as compound 6O, exhibit higher affinity for HCAR3, and how subtle variations in the orthosteric binding pocket confer receptor specificity. Such insights underpin the rational design of hypolipidemic agents targeting lipid metabolism regulation with improved safety profiles.

Methods and Experimental Design Insights

To address their research question, the authors expressed HCAR3-Gi and HCAR2-Gi protein complexes in Sf9 cells, then isolated and reconstituted these complexes for cryo-EM analysis. Structures were resolved for HCAR3 bound to four different agonists (compound 6O, D-phenyllactic acid, IBC293, and Acifran), with resolutions ranging from 3.05 Å to 3.31 Å. For HCAR2, the Acifran-bound complex was resolved at 2.72 Å. Complementary functional assays were performed using cAMP measurements in HEK-293 cells to validate the impact of specific residue variations on receptor activation and ligand selectivity. Structural models and cryo-EM density maps were deposited in public databases, ensuring reproducibility and transparency.

Core Findings and Why They Matter

Structural analysis revealed two key determinants of ligand selectivity in HCAR3 versus HCAR2:

• π–π Interaction at F107^3.32: HCAR3 features a phenylalanine (F107^3.32) at a critical binding site, whereas HCAR2 has leucine at the same position (L107^3.32). This substitution enables π–π stacking interactions with aromatic ligands in HCAR3, enhancing affinity and selectivity.
• Binding Pocket Volume and Residue Differences: Variations at V/L83^2.60, Y/N86^2.63, and S/W91^2.48 modulate the size and polarity of the ligand-binding pocket, further influencing agonist specificity and efficacy.

Among tested agonists, compound 6O achieved the highest affinity for HCAR3 by fully occupying both R1 and R2 regions of the orthosteric site. Acifran, a selective HM74A/GPR109A and GPR109B agonist, was shown to bind both HCAR2 and HCAR3, but with distinct interaction profiles explained by the above structural features. These findings directly support the rational development of metabolic disorder research compounds with refined selectivity, reducing the likelihood of HCAR2-associated adverse effects (Ye et al., 2025).

Protocol Parameters

• Receptor Expression: Express HCAR3-Gi or HCAR2-Gi complexes in Sf9 insect cells for optimal GPCR folding and stabilization.
• Agonist Incubation: Incubate purified complexes with selective agonists (e.g., Acifran) prior to cryo-EM grid preparation; recommended concentration 10–50 μM, as used in referenced protocols.
• Functional Assays: Use cAMP readout in HEK-293 cells to confirm receptor activation and ligand selectivity.
• Structural Analysis: Employ cryo-EM at 2.7–3.3 Å resolution to resolve ligand-receptor complexes and identify critical binding interactions.
• Data Deposition: Deposit atomic coordinates and density maps in the Protein Data Bank and Electron Microscopy Data Bank for reproducibility.

Comparison with Existing Internal Articles

Several recent internal resources contextualize and expand upon the structural findings of Ye et al. (2025). For example, "Structural Mechanisms of HCAR3 Agonist Selectivity Revealed by Cryo-EM" summarizes the structural determinants unveiled in the reference study and highlights the significance for rational agonist design. Meanwhile, "Precision Agonism: Harnessing Acifran to Decode Lipid Sig..." integrates these mechanistic insights into translational research strategies, emphasizing the value of Acifran as a tool for dissecting lipid signaling pathway modulation. Collectively, these articles reinforce how structural biology advances are informing both the theoretical and practical use of hypolipidemic agents for lipid metabolism research.

Limitations and Transferability

Although the structural resolution achieved by Ye et al. is high and the findings are robust, several limitations are notable. First, the use of recombinant insect cell systems and stabilized Gi complexes may not capture the full spectrum of physiological receptor dynamics seen in native tissues. Second, while cryo-EM snapshots provide atomic-level detail, they do not account for allosteric modulation or dynamic conformational changes that may influence ligand efficacy in vivo. Finally, the study focuses on a select panel of agonists, including Acifran, and further work is needed to generalize the principles to broader chemical classes and endogenous metabolites. Nevertheless, the transferability of these structural findings to drug discovery and metabolic disorder research is strong, especially as they elucidate actionable binding determinants and functional consequences.

Research Support Resources

To facilitate the translation of these structural insights into practical workflows, researchers can incorporate validated agonists such as Acifran (SKU B6848) into receptor-ligand interaction studies and lipid metabolism assays. Acifran, as a selective HM74A/GPR109A and GPR109B agonist, is suitable for probing lipid metabolism regulation and dissecting lipid signaling pathways in experimental settings. For further methodological details, the internal resource on workflow strategies with Acifran provides actionable guidance. When using Acifran, follow recommended storage and solution guidelines to maintain compound integrity and reproducibility. For researchers seeking reliable sources of Acifran for metabolic disorder research, APExBIO offers detailed product specifications and usage recommendations.